Sep 23, 2019 8:45 am EDT Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa
Aug 9, 2019 4:15 pm EDT Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
Jul 25, 2019 9:15 am EDT Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA
Jun 26, 2019 8:00 am EDT Abeona Therapeutics Appoints Dr. Victor Paulus Senior Vice President of Regulatory Affairs
Jun 18, 2019 8:29 am EDT Abeona Therapeutics Receives FDA Fast Track Designation for ABO-202 AAV9 Gene Therapy in CLN1 Disease
May 21, 2019 8:00 am EDT Abeona Therapeutics Announces FDA Clearance of Investigational New Drug Application for ABO-202 Gene Therapy in CLN1 Disease
May 14, 2019 8:00 am EDT Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB)
May 10, 2019 4:15 pm EDT Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
May 8, 2019 8:30 am EDT Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
